

44th EORTC-PAMM

February 7th to 10th 2024 - Marseille, France

AMPHITHÉÂTRE GASTAUT
JARDINS DU PHARO, AIX-MARSEILLE UNIVERSITÉ

PAMM
PHARMACOLOGY & MOLECULAR
MECHANISMS GROUP

EORTC
The future of cancer therapy

CONQUERING CANCER TOGETHER: UNITING MINDS, ADVANCING TREATMENTS



THEY SUPPORT US

Pierre Fabre

SERVIER®
moved by you

Bristol Myers Squibb®

Pfizer

Seagen®

AstraZeneca®

GILEAD

MCE®
Merck Serono

CDF Cancer Drug Resistance



Daiichi-Sankyo

MERCK

WWW.PAMM-MEETING.COM

WEDNESDAY 7th

03.00 PM
06.30 PM

- 15:00 EDUCATIONAL SESSION
17:30

Organizing committee:

Eddy Pasquier (FR), Elisa Giovannetti (NL), Véronique Debien (FR), Daniela Carbone (IT), Chiara Deiana (IT), Marion Le Grand (FR)

SESSION 1: A Battle on the Utility of Pharmacology in the Era of Personalized Medicine: Panacea or Placebo?

Nicolas André (FR) & Joseph Ciccolini (FR)

SESSION 2: Role of PAMM Early Career Investigators in the EORTC

SESSION 3: Brainstorming on transversal projects at the PAMM EORTC

- 17:30
18:30 PAMM Board Meeting (private)

- 18:30 Welcome reception in the exhibition hall

THURSDAY 8th

09.00 AM
08.00 PM

SEVERAL WAYS TO TARGETING CANCER - SESSION 1

- 09:00 **ADCs in Breast cancer,**
Maria Fernanda Moselle (FR)

- 09:30 **Targeting lipid metabolism in melanoma,**
Paola Perego (IT)

Young Investigator Session 1 - New drugs and scaffolds

- Unraveling the poly-pharmacology of beta-blockers in neuroblastoma using chemo-proteomics approaches**
Baptiste Mouysset (FR)

- 10:00 **Ezurpimtrostat autophagy blocker, a palmitoyl-protein thioesterase 1 (PPT1) inhibitor, and atezolizumab/bevacizumab triple combination regimen enhances antitumor efficacy in hepatocellular carcinoma**
Eloïne Bestion (FR)

- 10:30 Coffee break & exhibition hall visit

- 11:00 **Gut microbiota as a new strategy to improve treatment benefit in HER2+ breast cancer**
Martina Di Modica (IT)

11:30	Convergence of Precision Oncology and Liquid Biopsy in Non-Small Cell Lung Cancer, <i>Umberto Malapelle (IT)</i>
12:00	PIERRE FABRE SYMPOSIUM
13:00	Unleashing Precision Medicine: The Impact of BRAF Inhibitors in Melanoma and Colorectal Cancer Therapies <i>Caroline Robert, Christelle de la Fouchardière, Joseph Ciccolini</i>
13:00	Lunch break & exhibition hall visit
SMALL MOLECULES & TARGETED THERAPIES - SESSION 2	
14:00	Controlling the balance differentiation/dedifferentiation in breast cancer cells: pharmacodynamics of Dendrogenine A and Oncosterone, <i>Ben Allal (FR)</i>
Young Investigator Session 2 - New Biomarkers & Targets	
<p>Unveiling the Therapeutic Potential of Novel FAK Inhibitors in Overcoming Acquired Resistance to EGFR-TKI in Non-Small Cell Lung Cancer <i>Geng Xu (NL)</i></p> <p>Glyco-Humanized polyclonal antibody, first in class immunotherapy against cancer <i>Firas Bassissi (FR)</i></p>	
14:30	Using high-throughput drug screening to reveal therapeutic vulnerabilities in patient-derived diffuse midline glioma models <i>Julie Lafont (FR)</i>
<p>Exploring new roles for XPF and SLX4 proteins in cancer cells <i>Lars Petter Jordheim (FR)</i></p> <p>Elevated Levels of Serum Thymidine Kinase 1 Predicts Poor Survival of Metastatic Prostate Cancer Patients Treated with Antiandrogens <i>Stig Linder (SW)</i></p>	
15:45	Coffee break & exhibition hall visit
16:15	Induced-proximity modalities for research and therapeutics: beyond targeted protein degradation <i>Gopal Sapkota (UK)</i>
16:45	Drug Interaction and oral bioavailability of Tyrosine Kinase Inhibitors: two sides of the same coin <i>Etienne Chatelut (FR)</i>
17:00	To kill or not to kill, is that the question? <i>José M. Padron (SP)</i>
17:15	Cheerful poster session
18:15	End of day
20:00	Social Event

FRIDAY 9th

09.00 AM
08.00 PM

- 09:00 **Burger-Kelland Lecture: Targeted therapy : a personal vision**
Gérard Milano (FR)

NEW CHALLENGES IN IMMUNOTHERAPY - SESSION 3

- 09:30 **Immunotoxicity management: when to challenge the guidelines?**
Caroline Robert (FR)

Young Investigator Session 3 - Pharmacometrics Tools for Precision Medicine

**Towards precision dosing of oral anticancer drugs in clinical routine:
Feasibility of a closed-loop Therapeutic Drug Monitoring process within
the ON-TARGET study**
Fenja Klima (DE)

- 10:00 **An open source whole-body physiologically based pharmacokinetic and quantitative systems pharmacology approach supporting large molecule oncology drug development**
Alexander Kulesza (DE)

- 10:30 Coffee break & exhibition hall visit

- 11:00 **De-escalating immunotherapy,**
Daniel Goldstein (IS)

- 11:30 **PK/PD of CarT cells,**
Anna Mc Laughlin (IRL)

- 12:00 **SERVIER SYMPOSIUM**

- 13:00 **Optimus project, how to implement it at an oncology portfolio level and how to decide what's worth to optimize?**
Najah Harouki, PhD



Example of dose optimization on an Immuno/Oncology asset in early development using modelling and simulation
Christelle Rodrigues, PhD

- 13:00 Lunch & exhibition hall visit

NEW SCAFFOLDS & MOLECULAR MECHANISMS - SESSION 4

- 14:00 **Bcl3 inhibitor: promises and pitfalls,**
Andy Westwell (UK)

- 14:30 **Germline Regulators as oncology therapeutic targets: Drugging a developmental transcription factor**
Ramsay McFarlane (UK)

Young Investigator Session 4 - Pancreatic Cancer, the last fortress

Exploring a potential pro-metastatic biomarker in pancreatic cancer using the innovative organotypic liver model

Annalisa Comandatore (IT)

Novel Imidazothiadiazoles Derivatives Targeting Focal Adhesion Kinase for PDAC Treatment: Synthesis, Characterization, and Mechanistic Insights

Daniela Carbone (IT)

15:00

Novel insights for DDB2 as a potent biomarker for the management of patients with PDAC

Julie Dardare (FR)

Evaluating the Effects of an Innovative Enzymatic Formulation on Pancreatic Cancer Cells Resistant to Gemcitabine

Belén Toledo (SP)

16:00

Coffee break & exhibition hall visit

16:30

Small Molecules & targeted therapies : the lung cancer model

Benjamin Besse, EORTC (BE)

17:00

Cheerful poster session

18:00

End of day

20:00

Congress dinner - La Nautique Restaurant

SATURDAY 10th

09.00 AM
12.20 PM

TOOLS FOR PREDICTIVE ONCOLOGY - SESSION 5

09:00

The PIONeeR trial,

Sébastien Benzekry (FR)

09:30

Pragmatic clinical trials at EORTC,

Denis Lacombe, EORTC (BE)

10:00

Coffee break & exhibition hall visit

10:30

Vesicles in NSCLC,

Kerstin Menck (DE)

11:00

Model-based strategies for dose individualization of anticancer drugs,

Maddalena Centanni (SE)

11:30

PAMM 2024 AWARDS

12:00

Closing remarks



An independent group committed to therapeutic progress to serve patient needs

Founded to serve health, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world.

servier.com

As a world leader in cardiology, our ambition is to become a renowned, focused and innovative player in oncology by targeting hard-to-treat cancers. We are also involved in neuroscience and immune-inflammatory diseases to increase the pace of therapeutic innovation.

To promote access to quality care for all, we also offer a range of quality generic medicines covering most pathologies.

In all these areas, we include the patient voice at each stage of the life cycle of a medicine.

SERVIER 
moved by you

L'association BRAFTOVI + MEKTOVI est indiquée dans le traitement des patients adultes atteints d'un mélanome non résécable ou métastatique porteur d'une mutation BRAF V600^{1,2}

BRAFTOVI® + MEKTOVI® :

UNE SOLUTION THÉRAPEUTIQUE POUR VOS PATIENTS DÈS LA 1ÈRE LIGNE DE TRAITEMENT

Explorez la dernière génération d'inhibiteurs de BRAF + MEK



Avec une démonstration d'un gain sur la PFS par rapport au vemurafenib, comme pour les autres associations anti-BRAF/anti-MEK, et malgré l'absence de démonstration sur la survie globale, contrairement aux autres associations anti-BRAF/anti-MEK par rapport à la monothérapie par vemurafenib ou dabrafenib, la Commission considère que l'association encorafenib-binimetinib est une option thérapeutique en 1^{re} ligne de traitement de patients adultes atteints de mélanome non résécable ou métastatique porteur d'une mutation BRAF V600.³



Pour une information complète notamment sur les contre-indications, les mises en garde et les précautions d'emploi, consultez les mentions légales de BRAFTOVI® - MEKTOVI®.

Liste I – Remb. Soc. Soc 100% - Agres Collac.
Médicament soumis à prescription hospitalière.
Prescription réservée aux spécialistes en oncologie ou aux médecins compétents en cancérologie.
Médicament nécessitant une surveillance particulière pendant le traitement.

1. Résumé des caractéristiques produits BRAFTOVI® Last Update: Pierre Fabre Médicament, 2022.

2. Résumé des caractéristiques produits MEKTOVI® Last Update: Pierre Fabre Médicament, 2020.

3. Avis de la Commission de la Transparence de l'association BRAFTOVI® (encorafenib) et MEKTOVI® (binimetinib) (12 juin 2019).

PAMM BOARD

Elisa Giovannetti, Amsterdam, The Netherlands (Chair)
Joseph Ciccolini, Marseille, France (Secretary)
Eric Raymond, Paris, France (Past-Chair)

SCIENTIFIC COMMITTEE

Etienne Chatelut, Toulouse, France
Joseph Ciccolini, Marseille, France
Elisa Giovannetti, Amsterdam, The Netherlands
Georg Hempel, Münster, Germany
Jose M. Padron, La Laguna, Spain
Paola Perego, Milan, Italy
Godefridus J. Peters, Amsterdam, The Netherlands
Roger M. Phillips, Huddersfield, UK
Eric Raymond, Paris, France
Andrew D. Westwell, Cardiff, UK

ORGANIZATION

Com&Co Group
15, Boulevard Grawitz,
13016 Marseille

Étienne Jarry
e.jarry@comnco.com
+33 (0)4 91 09 70 53

Alexia Gelineau
a.gelineau@comnco.com
+33 (0)6 27 06 32 32

LOCAL ORGANIZING COMMITTEE

Joseph Ciccolini, Marseille, France

INTERNATIONAL FACULTY

Ben Allal, Toulouse, France
Nicolas André, Marseille, France
Sébastien Benzekry, Marseille, France
Benjamin Besse, EORTC, Brussels, Belgium
Maddalena Centanni, Uppsala, Sweden
Etienne Chatelut, Toulouse, France
Joseph Ciccolini, Marseille, France
Christelle de la Fouchardière, Lyon, France
Martina Di Modica, Milan, Italy
Daniel Goldstein, Tel Aviv, Israel
Denis Lacombe, EORTC, Brussels, Belgium
Umberto Malapelle, Naples, Italy
Ramsay McFarlane, Bangor, United-Kingdom
Anna McLaughlin, Dublin, Ireland
Kerstin Menck, Munster, Germany
Gérard Milano, Nice, France
Maria Fernanda Moselle, Villejuif, France
Jose M. Padron, La Laguna, Spain
Paola Perego, Milan, Italy
Caroline Robert, Villejuif, France
Gopal Sapkota, Dundee, United-Kingdom
Andrew D. Westwell, Cardiff, United-Kingdom

CONGRESS VENUE

Amphithéâtre Gastaut,
Jardins du Pharo,
Aix-Marseille Université
13007 Marseille, France



THEY SUPPORT US



CDF Cancer Drug Resistance